Symposium Overview
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently available
anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and
increasing the risk for serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects
the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support
a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary
stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This live, CE-certified symposium
will explore novel factor XIa inhibitors currently under investigation and outline anticoagulation’s exciting future.
Christopher B. Granger, MD
Donald F. Fortin, M.D. Distinguished
Professor of Medicine
Duke University Medical Center
Durham, NC
Manesh R. Patel, MD
Richard S. Stack Distinguished Professor
Chief, Division of Cardiology
Co-Director Duke Heart Center
Duke Clinical Research Institute
Duke University
Durham, NC
M. Cecilia Bahit, MD
Chief of Cardiology
INECO Neurociencias
Rosario, Argentina
Elaine Hylek, MD, MPH
Professor of Medicine
Boston University School of Medicine
Boston, MA
5:15pm
–
Registration & Reception - Enjoy delicious food & drink
6:00pm
–
Welcome and Introduction
–
The DOAC Revolution: What Have We Learned? – Dr. Granger
–
While the DOAC Revolution Has Occurred, 40-50% of Patients Remain Untreated…Why? – Dr. Hylek
–
While DOACs are Good for Some Things, They Aren’t for Everyone – Dr. Bahit
–
The Path Forward: What’s On The Horizon? – Dr. Patel
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team approach intended for clinical cardiologists,
emergency medicine physicians, hematologists, hospitalists, neurologists, primary care physicians, vascular medicine practitioners, and
vascular surgeons, as well as other clinicians involved in the management of patients with anticoagulation.
Learning Objectives
After completing this activity, the participant should be better able to:
- Review the currently available therapeutics and how they affect multiple pathways involved in the coagulation cascade, thereby
increasing the potential for serious bleeds
- Review current decision pathways for initiation of anticoagulation treatment and shared patient-physician decision-making, emphasizing
potential prescriber bias that limits more widespread adoption of DOAC therapy
- Review cardiac and non-cardiac patient populations where DOACs have limitations or contraindications
- Discuss factor XI and factor XIa inhibition and review new and emerging anticoagulation pharmacotherapy for VTE, AF, secondary stroke
prevention, and post-MI